• Bloomberg

  • SHARE

Drugmaker Daiichi Sankyo Co. won approval to sell the antibiotic Gracevit in its home market.

The Health, Labor and Welfare Ministry approved Gracevit as a broad-spectrum antibacterial agent on Friday, Tokyo-based Daiichi said in a statement on its Web site Monday. The medicine, which may be prescribed as a new quinolone oral antibacterial agent, is approved in 50-mg doses and in powder form, the company said.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW